Menée à partir des données 1988-2007 d'un registre américain portant sur 8 579 patients atteints d'un cancer du poumon non à petites cellules de stade I, cette étude compare, du point de vue de la survie globale à 5 ans, l'efficacité d'un traitement chirurgical et d'une radiothérapie

Outcomes following surgical treatment compared to radiation for stage I NSCLC: A SEER database analysis

Monirul Islam, K. M. ; Shostrom, Valerie ; Kessinger, Anne ; Ganti, Apar Kishor

Introduction : Outcomes following surgery are better than following radiation therapy (RT), for stage I NSCLC. Whether this is due to selection of healthier patients for surgery is unclear. This study was undertaken to compare outcomes between surgical patients and patients who were surgical candidates but did not receive surgery. Methods : Data of patients with stage I NSCLC between 1988 and 2007, included in the SEER database were analyzed. Overall survival (OS) was examined by treatment type [...]

A partir d'une revue systématique de la littérature publiée entre janvier 1995 et octobre 2010 (1 essai randomisé, 57 articles portant sur 53 études comparatives, 19 064 patients), cette méta-analyse compare, du point de vue de la qualité des marges de résection et de la morbidité associée à l'opération, l'efficacité d'une prostatectomie laparoscopique assistée par robot et d'une prostatectomie laparoscopique standard en remplacement d'une prostatectomie radicale par voie ouverte pour traiter un cancer localisé de la prostate

Relative effectiveness of robot-assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of localised prostate cancer : a systematic review and mixed treatment comparison meta-analysis

Robertson, Clare ; Close, Andrew ; Fraser, Cynthia ; Gurung, Tara ; Jia, Xueli ; Sharma, Pawana ; Vale, Luke ; Ramsay, Craig ; Pickard, Robert

Objective : To compare the effectiveness of robot-assisted and standard laparoscopic prostatectomy. Methods : A care pathway was described. We performed a systematic literature review based on a search of Medline, Medline in Process, Embase, Biosis, Science Citation Index, Cochrane Controlled Trials Register, Current Controlled Trials, Clinical Trials, WHO International Clinical Trials Registry and NIH Reporter, the Health Technology Assessment databases, the Database of Abstracts of Reviews of [...]

Menée à partir de données d'un registre américain portant sur 1 413 patients âgés de 66 ans ou plus et atteints d'un cancer de la glotte de stade précoce diagnostiqué entre 1992 et 2007, cette étude évalue, par rapport à une intervention chirurgicale, le risque actuariel à 10 ans des événements cérébrovasculaires indésirables après une radiothérapie

Risk of Cerebrovascular Events in Elderly Patients After Radiation Therapy Versus Surgery for Early-Stage Glottic Cancer

Hong, Julian C. ; Kruser, Tim J. ; Gondi, Vinai ; Mohindra, Pranshu ; Cannon, Donald M. ; Harari, Paul M. ; Bentzen, Søren M.

Purpose : Comprehensive neck radiation therapy (RT) has been shown to increase cerebrovascular disease (CVD) risk in advanced-stage head-and-neck cancer. We assessed whether more limited neck RT used for early-stage (T1-T2 N0) glottic cancer is associated with increased CVD risk, using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. Methods and Materials : We identified patients ≥66 years of age with early-stage glottic laryngeal cancer from SEER diagnosed from [...]

Menée in vitro et in vivo, cette étude suggère l'intérêt de développer des agents ciblant les protéines MKL 1/2 pour le traitement d'un carcinome hépatocellulaire présentant une délétion du gène suppresseur de tumeurs DLC1

Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence

Hampl, Veronika ; Martin, Claudia ; Aigner, Achim ; Hoebel, Sabrina ; Singer, Stephan ; Frank, Natalie ; Sarikas, Antonio ; Ebert, Oliver ; Prywes, Ron ; Gudermann, Thomas ; Muehlich, Susanne

Megakaryoblastic leukaemia 1 and 2 (MKL1/2) are coactivators of the transcription factor serum response factor (SRF). Here, we provide evidence that depletion of MKL1 and 2 abolishes hepatocellular carcinoma (HCC) xenograft growth. Loss of the tumour suppressor deleted in liver cancer 1 (DLC1) and the subsequent activation of RhoA were prerequisites for MKL1/2 knockdown-mediated growth arrest. We identified oncogene-induced senescence as the molecular mechanism underlying the anti-proliferative [...]

Cet article passe en revue les perspectives offertes par les connaissances sur le rôle biologique de l'endothéline 1 pour développer de nouveaux traitements des cancers

Endothelin 1 in cancer: biological implications and therapeutic opportunities

Rosano, Laura ; Spinella, Francesca ; Bagnato, Anna

Activation of autocrine and paracrine signalling by endothelin 1 (ET1) binding to its receptors elicits pleiotropic effects on tumour cells and on the host microenvironment. This activation modulates cell proliferation, apoptosis, migration, epithelial-to-mesenchymal transition, chemoresistance and neovascularization, thus providing a strong rationale for targeting ET1 receptors in cancer. In this Review, we discuss the advances in our understanding of the diverse biological roles of ET1 in [...]

Cet article passe en revue les perspectives offertes par le ciblage de la protéine HLA-G pour le développement de nouveaux traitements des cancers

Molecular Pathways: Human leukocyte antigen G (HLA-G)

Curigliano, Giuseppe ; Criscitiello, Carmen ; Gelao, Lucia ; Goldhirsch, Aron

Human leukocyte antigen G (HLA-G) is a non-classical major histocompatibility complex (MHC) class I molecule that exerts important tolerogenic functions. Its main physiological expression occurs in placenta where participates in the maternal tolerance toward the fetus. HLA-G expression was found in embryonic tissues, in adult immune privileged organs, and in cells of the hematopoietic lineage. It is expressed in various types of primary solid (melanoma, head and neck, lung, urogenital, [...]

Menée in vitro et in vivo, cette étude met en évidence des mécanismes par lesquels, en augmentant l'activité de p53, le dasatinib renforce l'efficacité de la daunorubicine dans le traitement des patients atteints d'une leucémie myéloïde aiguë

The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cell by chemotherapeutic agents

Dos Santos, Cedric ; McDonald, Tinisha ; Ho, Yin Wei ; Liu, Hongjun ; Lin, Allen ; Forman, Stephen J. ; Kuo, Ya-Huei ; Bhatia, Ravi

The SRC Family Kinases (SFKs) and the receptor tyrosine kinase c-Kit, are activated in human acute myeloid leukemia (AML) cells. We show here that the SFKs LYN, HCK or FGR are overexpressed and activated in AML progenitor cells. Treatment with the SFK and c-KIT inhibitor dasatinib selectively inhibits human AML stem/progenitor cell growth in vitro. Importantly, dasatinib markedly increases the elimination of AML stem cells capable of engrafting immunodeficient mice by chemotherapeutic agents. [...]

Menée in vitro, cette étude met en évidence des mécanismes par lesquels le récepteur ErbB3 induit une résistance à un inhibiteur de BRAF ou MEK dans le traitement d'un mélanome avancé

Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies

Fattore, Luigi ; Marra, Emanuele ; Pisanu, Maria ; Noto, Alessia ; de Vitis, Claudia ; Belleudi, Francesca ; Aurisicchio, Luigi ; Mancini, Rita ; Torrisi, Maria ; Ascierto, Paolo ; Ciliberto, Gennaro

BACKGROUND:Treatment of advanced melanoma has been improved with the advent of the BRAF inhibitors. However, a limitation to such treatment is the occurrence of resistance. Several mechanisms have been identified to be responsible for the development of resistance, either MEK-dependent or MEK-independent. In order to overcome resistance due to reactivation of MEK signaling, MEK inhibitors are being clinically developed with promising results. However, also in this case resistance inevitably [...]

Menée in vitro, cette étude met en évidence des mécanismes par lesquels la protéine CD44 contribue à rendre les cellules de myélome multiple résistantes au lénalidomide

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

Bjorklund, C. C. ; Baladandayuthapani, V. ; Lin, H. Y. ; Jones, R. J. ; Kuiatse, I. ; Wang, H. ; Yang, J. ; Shah, J. J. ; Thomas, S. K. ; Wang, M. ; Weber, D. M. ; Orlowski, R. Z.

Resistance of myeloma to lenalidomide is an emerging clinical problem, and though it has been associated in part with activation of Wnt/

Menée in vitro et à l'aide de xénogreffes, cette étude met en évidence un mécanisme de résistance à l'erlotinib dans le traitement d'un cancer du poumon non à petites cellules et suggère que le niclosamide permet de restaurer la sensibilité des cellules cancéreuses à l'erlotinib

Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer

Li, Rui ; Hu, Zhongliang ; Sun, Shi-Yong ; Chen, Zhuo G. ; Owonikoko, Taofeek K. ; Sica, Gabriel L. ; Ramalingam, Suresh S. ; Curran, Walter J. ; Khuri, Fadlo R. ; Deng, Xingming

The emergence of resistance to epidermal growth factor receptor (EGFR) inhibitor therapy is a major clinical problem for patients with non-small cell lung cancer (NSCLC). The mechanisms underlying tumor resistance to inhibitors of the kinase activity of EGFR are not fully understood. Here we found that inhibition of EGFR by erlotinib induces STAT3 phosphorylation at Tyr705 in association with increased Bcl2/Bcl-XL at both mRNA and protein levels in various human lung cancer cells. PTPMeg2 is a [...]

Menée sur des lignées cellulaires de cancer de la vessie, cette étude met en évidence des mécanismes d'action différents du pazopanib et du sunitinib

Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells

Santoni, M. ; Amantini, C. ; Morelli, M. B. ; Liberati, S. ; Farfariello, V. ; Nabissi, M. ; Bonfili, L. ; Eleuteri, A. M. ; Mozzicafreddo, M. ; Burattini, L. ; Berardi, R. ; Cascinu, S. ; Santoni, G.

Background: Tyrosine kinase inhibitors (TKI) such as sunitinib and pazopanib display their efficacy in a variety of solid tumours. However, their use in therapy is limited by the lack of evidence about the ability to induce cell death in cancer cells. Our aim was to evaluate cytotoxic effects induced by sunitinib and pazopanib in 5637 and J82 bladder cancer cell lines. Methods: Cell viability was tested by MTT assay. Autophagy was evaluated by western blot using anti-LC3 and anti-p62 [...]

Cet article analyse le rôle de la chimiothérapie dans la survenue d'une hypertension, résume les règles générales en matière de prise en charge thérapeutique de l'hypertension chez les patients traités pour un cancer et évalue les effets des hypertenseurs sur le risque de cancer

Arterial hypertension and cancer

Milan, Alberto ; Puglisi, Elisabetta ; Ferrari, Laura ; Bruno, Giulia ; Losano, Isabel ; Veglio, Franco

Arterial hypertension and cancer are two of the most important causes of mortality in the world; correlations between these two clinical entities are complex and various. Cancer therapy using old (e.g., mitotic spindle poisons) as well as new (e.g., monoclonal antibody) drugs may cause arterial hypertension through different mechanisms; sometimes the increase of blood pressure levels may be responsible for chemotherapy withdrawal. Among newer cancer therapies, drugs interacting with the VEGF [...]

Mené sur 201 patients âgés atteints d'une leucémie myéloïde aiguë, cet essai randomisé évalue, du point de vue de la survie sans événement, l'efficacité du sorafenib en complément d'un traitement d'induction et de consolidation à base de cytarabine et daunorubicine

Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial

Serve, Hubert ; Krug, Utz ; Wagner, Ruth ; Sauerland, M. Cristina ; Heinecke, Achim ; Brunnberg, Uta ; Schaich, Markus ; Ottmann, Oliver ; Duyster, Justus ; Wandt, Hannes ; Fischer, Thomas ; Giagounidis, Aristoteles ; Neubauer, Andreas ; Reichle, Albrecht ; Aulitzky, Walter ; Noppeney, Richard ; Blau, Igor ; Kunzmann, Volker ; Stuhlmann, Reingard ; Krämer, Alwin ; Kreuzer, Karl-Anton ; Brandts, Christian ; Steffen, Björn ; Thiede, Christian ; Müller-Tidow, Carsten ; Ehninger, Gerhard ; Berdel, Wolfgang E.

Purpose The prognosis of elderly patients with acute myeloid leukemia (AML) is still dismal even with intensive chemotherapy. In this trial, we compared the antileukemic activity of standard induction and consolidation therapy with or without the addition of the kinase inhibitor sorafenib in elderly patients with AML. Patients and Methods All patients received standard cytarabine and daunorubicin induction (7+3 regimen) and up to two cycles of intermediate-dose cytarabine consolidation. Two [...]

A partir de données portant sur 241 patients atteints d'un lymphome non hodgkinien à cellules T, cette étude évalue l'efficacité d'une greffe autologue et d'une greffe allogénique de cellules hématopoïétiques

Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma

Smith, Sonali M. ; Burns, Linda J. ; van Besien, Koen ; LeRademacher, Jennifer ; He, Wensheng ; Fenske, Timothy S. ; Suzuki, Ritsuro ; Hsu, Jack W. ; Schouten, Harry C. ; Hale, Gregory A. ; Holmberg, Leona A. ; Sureda, Anna ; Freytes, Cesar O. ; Maziarz, Richard Thomas ; Inwards, David J. ; Gale, Robert Peter ; Gross, Thomas G. ; Cairo, Mitchell S. ; Costa, Luciano J. ; Lazarus, Hillard M. ; Wiernik, Peter H. ; Maharaj, Dipnarine ; Laport, Ginna G. ; Montoto, Silvia ; Hari, Parameswaran N.

Purpose To analyze outcomes of hematopoietic cell transplantation (HCT) in T-cell non-Hodgkin lymphoma. Patients and Methods Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 angioimmunoblastic T-cell lymphoma) undergoing autologous HCT (autoHCT; n = 115; median age, 43 years) or allogeneic HCT (alloHCT; n = 126; median age, 38 years) were analyzed. Primary outcomes were nonrelapse mortality (NRM), relapse/progression, [...]

A partir de données portant sur 1 572 patients atteints d'un myélome multiple inclus dans des essais de phase III, cette méta-analyse évalue, du point de vue de la survie sans progression, l'efficacité d'un traitement d'induction à base de bortezomib

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

Sonneveld, Pieter ; Goldschmidt, Hartmut ; Rosiñol, Laura ; Bladé, Joan ; Lahuerta, Juan José ; Cavo, Michele ; Tacchetti, Paola ; Zamagni, Elena ; Attal, Michel ; Lokhorst, Henk M. ; Desai, Avinash ; Cakana, Andrew ; Liu, Kevin ; van de Velde, Helgi ; Esseltine, Dixie-Lee ; Moreau, Philippe

Purpose To characterize efficacy and safety of bortezomib-based versus nonbortezomib-based induction regimens through an integrated analysis of data from phase III studies in transplantation-eligible patients with previously untreated myeloma. Patients and Methods Patient-level data from the IFM 2005-01 (bortezomib-dexamethasone v vincristine-doxorubicin-dexamethasone [VAD] induction), HOVON-65/GMMG-HD4 (bortezomib-doxorubicin-dexamethasone v VAD), and PETHEMA GEM05MENOS65 [...]

Mené sur 119 patients atteints d'un myélome multiple asymptomatique à haut risque, cet essai de phase III évalue, du point de vue du délai avant l'apparition de symptômes, l'efficacité d'un traitement d'induction à base de lénalidomide et dexaméthasone, suivi par un traitement d'entretien à base de lénalidomide (durée médiane de suivi : 40 mois)

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

Mateos, María-Victoria ; Hernández, Miguel-Teodoro ; Giraldo, Pilar ; de la Rubia, Javier ; de Arriba, Felipe ; Corral, Lucía López ; Rosiñol, Laura ; Paiva, Bruno ; Palomera, Luis ; Bargay, Joan ; Oriol, Albert ; Prósper, Felipe ; López, Javier ; Olavarría, Eduardo ; Quintana, Nuria ; García, José-Luis ; Bladé, Joan ; Lahuerta, Juan-José ; San Miguel, Jesús-F.

Background : For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention. Methods : In this randomized, open-label, phase 3 trial, we randomly assigned 119 patients with high-risk smoldering myeloma to treatment or observation. Patients in the treatment group received an induction regimen (lenalidomide at a dose of 25 mg per day on days 1 to 21, plus [...]

Mené sur 142 patientes atteintes d'un cancer avancé de l'ovaire, cet essai de phase II évalue, du point de vue de la survie sans progression, l'efficacité de l'enzastaurine en complément d'une chimiothérapie combinant carboplatine et paclitaxel

Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer

Vergote, Ignace B. ; Chekerov, Radoslav ; Amant, Frederic ; Harter, Philipp ; Casado, Antonio ; Emerich, Janusz ; Bauknecht, Thomas ; Mansouri, Kambiz ; Myrand, Scott P. ; Nguyen, Tuan S. ; Shi, Peipei ; Sehouli, Jalid

Purpose Enzastaurin is an oral serine/threonine kinase inhibitor antitumor agent. Our phase II trial tested the efficacy and safety of enzastaurin added to a standard carboplatin/paclitaxel chemotherapy regimen in patients with newly diagnosed advanced ovarian cancer. Patients and Methods This was a randomized, placebo-controlled study in patients with International Federation of Gynecology and Obstetrics stage IIB to IV ovarian, fallopian tube, or peritoneal epithelial carcinoma. Patients were [...]

Mené sur 73 patients atteints d'un adénocarcinome canalaire du pancréas ayant fait l'objet d'une résection, cet essai de phase II évalue, du point de vue du taux de survie sans événement à 18 mois, l'efficacité de l'ajout de cetuximab à la gemcitabine

Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)

Fensterer, H. ; Schade-Brittinger, C. ; Müller, H. -H. ; Tebbe, S. ; Fass, J. ; Lindig, U. ; Settmacher, U. ; Schmidt, W. E. ; Märten, A. ; Ebert, M. P. ; Kornmann, M. ; Hofheinz, R. ; Endlicher, E. ; Brendel, C. ; Barth, P. J. ; Bartsch, D. K. ; Michl, P. ; Gress, T. M. ; for the Arbeitsgemeinschaft Internistische Onkologie

Background To investigate whether addition of cetuximab to standard adjuvant chemotherapy with gemcitabine improves outcome in pancreatic cancer, specifically whether the rate of disease-free survival (DFS) at 18 months (primary end point) exceeds the previously reported 35% of gemcitabine alone. Patients and methods Prospective, open-label, multicenter, nonrandomized phase II study in 76 patients with R0- or R1-resected ductal adenocarcinoma of the pancreas included between October 2006 and [...]

Cet article passe en revue les travaux récents sur les stratégies thérapeutiques à mettre en oeuvre en cas de résistance au gefitinib ou à l'erlotinib chez les patients atteints d'un cancer avancé du poumon non à petites cellules avec mutations du gène EGFR

Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma

Cadranel, Jacques ; Ruppert, Anne-Marie ; Beau-Faller, Michèle ; Wislez, Marie

Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib. Cancer patients harboring activating EGFR mutations benefit from first-line TKI therapy. Yet 10% of patients present a primary TKI resistance, while 50% of the others develop a secondary resistance within 9–12 months after starting TKI. The RECIST's [...]

A partir de données issues de trois essais de phase III évaluant un traitement de première ligne chez des patientes atteintes d'un cancer métastatique du sein HER- (2 447 patientes au total), cette méta-analyse évalue l'efficacité du bevacizumab en complément d'une chimiothérapie

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients

Miles, D. W. ; Dieras, V. ; Cortés, J. ; Duenne, A.-A. ; Yi, J. ; O'Shaughnessy, J.

Background Bevacizumab has consistently demonstrated improved progression-free survival (PFS) and response rate when combined with first-line chemotherapy for HER2-negative metastatic breast cancer (mBC). However, the lack of a significant overall survival (OS) difference continues to attract debate, and identification of patients deriving greatest benefit from bevacizumab remains elusive. Patients and methods Individual patient data from three randomised phase III trials in the first-line [...]

Cet article passe en revue les travaux récents sur l'intérêt des hormonothérapies néoadjuvantes pour les patientes atteintes d'un cancer du sein HR+

Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review

Charehbili, A. ; Fontein, D. B. Y. ; Kroep, J. R. ; Liefers, G. J. ; Mieog, J. S. D. ; Nortier, J. W. R. ; van de Velde, C. J. H.

In recent years, studies investigating neoadjuvant therapies have been emerging, because of the additional benefits it provides in terms of facilitating less extensive surgery and the possibility of investigating tumor biological features and response. Neoadjuvant hormonal therapy (NHT) is, in general, considered to be a suitable option for hormone receptor (HR)-positive patients who are unfit for chemotherapy or surgery, and is increasingly being utilized to achieve tumor downsizing before [...]

Mené sur 39 patients atteints d'un adénocarcinome avancé des voies biliaires, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du sorafenib à un traitement combinant gemcitabine et cisplatine

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas

Lee, J. K. ; Capanu, M. ; O'Reilly, E. M. ; Ma, J. ; Chou, J. F. ; Shia, J. ; Katz, S. S. ; Gansukh, B. ; Reidy-Lagunes, D. ; Segal, N. H. ; Yu, K. H. ; Chung, K. Y. ; Saltz, L. B. ; Abou-Alfa, G. K.

Background: This study evaluated the addition of sorafenib to gemcitabine and cisplatin in biliary adenocarcinoma first-line therapy. Methods: Patients with advanced biliary adenocarcinomas received gemcitabine 1000mgm−2 and cisplatin 25mgm−2 on a 2 weeks on/1 week off cycle and sorafenib 400mg twice daily. After the initial 16 patients were enrolled, the chemotherapy doses were amended in view of grade 3 and 4 hand–foot skin reaction and haematologic toxicity. Subsequently, 21 patients [...]

Menée sur 29 patients atteints d'un mélanome métastatique non résécable traité entre 2005 et 2011, cette étude rétrospective évalue la survie globale et le taux d'événements indésirables associés à un traitement combinant de manière concomitante une radiothérapie et une immunothérapie à base d'Ipilimumab

Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma

Barker, Christopher A. ; Postow, Michael A. ; Khan, Shaheer A. ; Beal, Kathryn ; Parhar, Preeti K. ; Yamada, Yoshiya ; Lee, Nancy Y. ; Wolchok, Jedd D.

Ipilimumab and radiotherapy are commonly used to treat unresectable and metastatic melanoma. Results from preclinical studies and case reports suggest a biologic interaction between these two treatments. To understand the clinical implications of the interaction, we carried out a retrospective study reviewing records of patients treated with ipilimumab and radiotherapy for melanoma at our institution between 2005 and 2011. The review included details of treatment, response, adverse events (AE), [...]

Menée à l'aide d'une xénogreffe de carcinome humain du rhinopharynx sur un modèle murin, cette étude analyse l'effet d'un traitement combinant le topotécan et une radiothérapie, administrée en fonction du rythme biologique, sur la sensibilité des cellules cancéreuses aux rayonnements ionisants, puis identifie les mécanismes associés

Synergistic Effect of Combination Topotecan and Chronomodulated Radiation Therapy on Xenografted Human Nasopharyngeal Carcinoma

Zhang, YanLing ; Chen, Xin ; Ren, PeiRong ; Su, Zhou ; Cao, HongYing ; Zhou, Jie ; Zou, XiaoYan ; Fu, ShaoZhi ; Lin, Sheng ; Fan, Juan ; Yang, Bo ; Sun, XiaoYang ; Zhou, Yan ; Chen, Yue ; Yang, LingLin ; Wu, JingBo

Purpose : To investigate the in vivo chronomodulated radiosensitizing effect of topotecan (TPT) on human nasopharyngeal carcinoma (NPC) and its possible mechanisms. Methods and Materials : Xenografted BALB/c (nu/nu) NPC mice were synchronized with an alternation of 12 hours of light from 0 to 12 hours after light onset (HALO) and 12 hours of darkness to establish a unified biological rhythm. Chronomodulated radiosensitization of TPT was investigated by analysis of tumor regrowth delay (TGD), [...]